{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-000964","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.035545+00:00","generated_at":"2026-05-16T01:12:27.388936+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"BioNexus Gene Lab Corp. completes Chemrex governance restructuring; appoints Matthew Barsing as Chairman","bullets":["Chemrex board streamlined to two directors: Matthew L. Barsing (Chairman) and Angeline Chong (Director, BioNexus CFO).","New officers expected in coming months; Chemrex remains wholly owned subsidiary under parent oversight.","July 2025 capital allocation framework approved for potential operational upgrades, subject to evaluation.","No definitive commitments on scope, timing, or scale of any initiative under evaluation."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-000964","json":"https://secwatch.observer/filing/0001477932-26-000964.json","markdown":"https://secwatch.observer/filing/0001477932-26-000964.md","text":"https://secwatch.observer/filing/0001477932-26-000964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793226000964/0001477932-26-000964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793226000964/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:12:27.388936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}